Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GD2 CAR T cells against human glioblastoma
Malvina Prapa, Chiara Chiavelli, Giulia Golinelli, et al.
npj Precision Oncology (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 60

Showing 26-50 of 60 citing articles:

CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View
Sara Capolla, Maria Rasool, Giuseppe Toffoli, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Hadeesha Piyadasa, Benjamin Oberlton, Mikaela Ribi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
Vincenzo Di Nunno, Marta Aprile, Lidia Gatto, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1042-1042
Open Access | Times Cited: 10
Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells
Haidy A. Saleh, Nicola Mitwasi, Martin Ullrich, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Chiara Chiavelli, Malvina Prapa, Giulia Rovesti, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions
Michael Goutnik, Alexandria Iakovidis, Megan Still, et al.
Neuro-Oncology Advances (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Joash D. Joy, Beatrice Malacrida, Florian Laforêts, et al.
Cancer Research (2024) Vol. 84, Iss. 15, pp. 2432-2449
Open Access | Times Cited: 3
Advances in CAR-T therapy for central nervous system tumors
Delian Zhou, Xiaojian Zhu, Yi Xiao
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapy
Haeyoun Choi, Tai‐Gyu Kim, Sin‐Soo Jeun, et al.
Cancer Letters (2023) Vol. 571, pp. 216335-216335
Closed Access | Times Cited: 7
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Abdolreza Esmaeilzadeh, Kaveh Hadiloo, Marjan Jabbari, et al.
Life Sciences (2023) Vol. 337, pp. 122381-122381
Closed Access | Times Cited: 6
Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification
Jason M. Tonne, Karol Budzik, Talia Fernandez Carrasco, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200852-200852
Open Access | Times Cited: 2
Therapeutic efficacy of IL-7/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer
Keisuke Ohta, Yukimi Sakoda, Keishi Adachi, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 9, pp. 2514-2524
Open Access | Times Cited: 2
CAR-iNKT cell therapy: mechanisms, advantages, and challenges
Zixuan Wang, Guangji Zhang
Current Research in Translational Medicine (2024) Vol. 73, Iss. 1, pp. 103488-103488
Closed Access | Times Cited: 2
Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK
Weihua Liu, Yu Zhao, Zhongfeng Liu, et al.
Cellular Oncology (2023) Vol. 46, Iss. 6, pp. 1747-1762
Closed Access | Times Cited: 6
Emerging Biomarkers for Immunotherapy in Glioblastoma
Nadia Mensali, Else Marit Inderberg
Cancers (2022) Vol. 14, Iss. 8, pp. 1940-1940
Open Access | Times Cited: 9
A Mathematical Model for On-Target Off-Tumor Effect of CAR-T Cells on Gliomas
Daniela Silva Santurio, Luciana Rodrigues Carvalho Barros
Frontiers in Systems Biology (2022) Vol. 2
Open Access | Times Cited: 9
Molecular and therapeutic effect of CRISPR in treating cancer
Sawani Rodrigo, Kaveesha Senasinghe, Sameer Quazi
Medical Oncology (2023) Vol. 40, Iss. 2
Open Access | Times Cited: 5
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 269-286
Closed Access | Times Cited: 5
Advanced T and Natural Killer Cell Therapy for Glioblastoma
Wan‐Soo Yoon, Dong‐Sup Chung
Journal of Korean Neurosurgical Society (2023) Vol. 66, Iss. 4, pp. 356-381
Open Access | Times Cited: 3
Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies
Qiyue Wang, Xiaofei Xin, Qihao Dai, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108527-108527
Closed Access | Times Cited: 3
Spatial transcriptomics in glioblastoma: is knowing the right zip code the key to the next therapeutic breakthrough?
Jack Shireman, Lingxin Cheng, Amiti Goel, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
A 3D hanging spheroid-filter plate for high-throughput drug testing and CAR T cell cytotoxicity assay
Zhenzhong Chen, Seokgyu Han, Sein Kim, et al.
The Analyst (2023) Vol. 149, Iss. 2, pp. 475-481
Closed Access | Times Cited: 3
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
Tessa Gargett, Lisa M. Ebert, Nga Truong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
Sjoerd Nota, David O. Osei-Hwedieh, David L. Drum, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5
Evaluation of Radiosensitization and Cytokine Modulation by Differentially PEGylated Gold Nanoparticles in Glioblastoma Cells
B. Kerr, Daniel J. Duffy, Caitríona E. McInerney, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10032-10032
Open Access | Times Cited: 2

Scroll to top